Company Filing History:
Years Active: 2018
Title: The Innovations of Dominique Louis Léon Swinnen
Introduction
Dominique Louis Léon Swinnen is a notable inventor based in Brussels, Belgium. He holds two patents, showcasing his contributions to scientific advancements in the biomedical field. His work focuses primarily on developing potent modulators for human tumor necrosis factor (TNF) activity, which can have significant implications for various human ailments.
Latest Patents
Swinnen's latest patents include a series of fused tricyclic imidazole derivatives that function as modulators of TNF activity. The first patent details dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, which are particularly beneficial in treating and preventing autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. The second patent describes substituted fused tricyclic imidazole derivatives, including dihydro-1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine and other analogs, which share similar therapeutic benefits.
Career Highlights
Dominique Swinnen is affiliated with UCB Biopharma Sprl, a leading global biopharmaceutical company that develops innovative medicines to improve the quality of life for people living with severe diseases. His position at this esteemed organization highlights his role in advancing medical research and drug development, particularly in the field of immunology.
Collaborations
Throughout his career, Swinnen has collaborated with distinguished professionals in the field. Notably, his coworkers Rikki Peter Alexander and Julien Alistair Brown contribute to the collective pursuit of innovative solutions in biomedical research and therapeutic development. Their teamwork fosters an environment ripe for groundbreaking discoveries that could impact various health concerns.
Conclusion
Dominique Louis Léon Swinnen's contributions through his patents and work at UCB Biopharma Sprl demonstrate his commitment to improving healthcare outcomes. By focusing on the modulation of TNF activity, he is paving the way for new treatments that have the potential to revolutionize care for individuals suffering from a range of debilitating conditions. His work exemplifies the vital role of inventors in driving innovation and enhancing human health.